

SUPPLEMENTARY MATERIAL TO

Synthesis of novel {[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles and assessment of their interactions with the D2 dopamine receptor

JELENA Z. PENJIŠEVIĆ^a, DEANA B. ANDRIĆ^b, VLADIMIR B. ŠUKALOVIĆ^a, GORAN M. ROGLIĆ^b, VUKIĆ ŠOŠKIĆ^c and SLAĐANA V. KOSTIĆ-RAJAČIĆ^{a*}

^a ICTM-Department of Chemistry, University of Belgrade, Njegoševa 12 11000 Belgrade, Serbia

^b Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11000 Belgrade, Serbia

^c Orgentec GmbH, Carl-Zeiss-Str. 49, 55129 Mainz, Germany

ANALYTICAL AND SPECTRAL DATA FOR THE SYNTHESIZED COMPOUNDS

Methyl 2-[4-(2-methoxyphenyl)piperazin-1-yl]acetate (3a):

Yield: 95.3 %; orange crystals m.p. 50 °C; IR (ATR, cm⁻¹): 2820.2, 1724.3, 1500.9, 1451.7, 1241.4, 1027.1, 751.3; ¹H-NMR (200 MHz, CDCl₃) δ: 2.75-2.80 (m, 4H, piperazine), 3.12-3.17 (m, 4H, piperazine), 3.29 (s, 2H, CH₂), 3.74 (s, 3H, -COCH₃), 3.85 (s, 3H, OCH₃), 6.84-7.01 (m, 4H, ArH); ¹³C-NMR (50 MHz, CDCl₃) δ: 50.22, 51.56, 53.20, 55.16, 59.43, 111.01, 118.11, 120.86, 122.86, 141.03, 152.10, 170.64; MS: m/z [M+H]⁺ calculated for C₁₄H₂₀N₂O₃ 265.15467, found 265.15493.

Ethyl 3-[4-(2-methoxyphenyl)piperazin-1-yl]propanoate (3b):

Yield: 84.2 %; oil; IR (ATR, cm⁻¹): 2818.6, 1734.0, 1501.0, 1452.7, 1241.3, 1026.5, 749.6; ¹H-NMR (200 MHz, CDCl₃) δ: 1.28 (t, 3H, J=7.4 Hz, CH₃), 2.51-2.59 (m, 2H, CH₂), 2.66-2.71 (m, 4H, piperazine), 2.75-2.83 (m, 2H, CH₂), 3.08-3.10 (m, 4H, piprazine), 3.86 (s, 3H, OCH₃), 4.16

*Corresponding author. E-mail: srkostic@chem.bg.ac.rs

26 (q, J=7.4 Hz, J=11.4 Hz, 2H, COCH₂), 6.84-7.03 (m, 4H, ArH); ¹³C-NMR (50 MHz, CDCl₃) δ: 27 14.04, 32.13, 50.39, 52.94, 53.45, 55.13, 60.17, 110.99, 118.00, 120.80, 122.73, 141.12, 152.08, 28 172.35; MS: m/z [M+H]⁺ calculated for C₁₆H₂₄N₂O₃, 293.18597, found 293.18584.

29

30 *Ethyl 4-[4-(2-methoxyphenyl)piperazin-1-yl]butanoate (3c):*

31 Yield: 86.6 %; oil; IR (ATR, cm⁻¹): 2817.0, 1732.8, 1501.1, 1452.5, 1241.3, 1028.1, 750.6; ¹H- 32 NMR (200 MHz, CDCl₃) δ: 1.26 (t, 3H, J= 7.4 Hz, CH₃), 1.78-1.93 (m, 2H, CH₂), 2.33-2.47 (m, 33 4H, CH₂), 2.63-2.66 (m, 4H, piperazine), 3.09 (s, 4H, piperazine), 3.86 (s, 3H, OCH₃), 4.13 (q, 34 2H, J= 6.6 Hz, J= 7.4 Hz, COCH₂), 6.83-7.04 (m, 4H, ArH); ¹³C-NMR (50 MHz, CDCl₃) δ: 14.11, 35 22.03, 32.19, 50.52, 53.23, 55.18, 57.64, 60.12, 111.01, 118.03, 120.84, 122.73, 141.25, 152.16, 36 173.49; MS: m/z [M+H]⁺ calculated for C₁₇H₂₆N₂O₃ 307.20162, found 307.20152.

37

38 *Methyl 5-[4-(2-methoxyphenyl)piperazin-1-yl]pentanoate (3d):*

39 Yield: 69.0 %; oil; IR (ATR, cm⁻¹): 2818.4, 1737.6, 1500.9, 1450.9, 1241.1, 1027.2, 751.1; ¹H- 40 NMR (200 MHz, CDCl₃) δ: 1.67-1.71 (m, 4H, CH₂), 2.35-2.38 (m, 2H, CH₂), 2.51-2.54(m, 2H, 41 CH₂), 2.76(s, 4H, piperazine), 3.17 (s, 4H, piperazine), 3.67 (S, 3H, CH₃), 3.86 (m, 3H, OCH₃), 42 6.85-7.02 (m, 4H, ArH); ¹³C-NMR (50 MHz, CDCl₃) δ: 22.41, 25.80, 33.35, 50.10, 50.90, 52.93, 43 54.78, 57.70, 110.64, 117.63, 120.47, 122.33, 140.85, 151.75, 173.40; MS: m/z [M+H]⁺ calculated 44 for C₁₇H₂₆N₂O₃ 307.20162, found 307.20075.

45

46 *Ethyl 6-[4-(2-methoxyphenyl)piperazin-1-yl]hexanoate (3e):*

47 Yield: 91.0%; oil; IR (ATR, cm⁻¹): 2814.2, 1734.5, 1501.2, 1452.5, 1240.9, 1029.8, 748.0; ¹H- 48 NMR (200 MHz, CDCl₃) δ: 1.22 (t, 3H, J=7.4 Hz, CH₃), 1.29-1.39 (m, 2H, CH₂), 1.45-1.71 (m, 49 4H, CH₂), 2.24-2.41 (m, 4H, CH₂), 2.61 (s, 4H, piperazine), 3.07 (s, 4H, piperazine), 3.82 (s, 3H, 50 OCH₃), 4.09 (q, 2H, J=6 Hz, J= 8 Hz, COCH₂), 6.80-7.00 (m, 4H, ArH); ¹³C-NMR (50 MHz, 51 CDCl₃) δ: 14.07, 24.72, 26.42, 26.96, 34.08, 50.47, 53.33 55.13, 58.42, 60.01, 110.95, 118.00, 52 120.80, 122.70, 141.23, 152.10, 173.59; MS: m/z [M+H]⁺ calculated for C₁₉H₃₀N₂O₃ 335.23292, 53 found 335.23342.

54

55 *Ethyl 7-[4-(2-methoxyphenyl)piperazin-1-yl]heptanoate (3f):*

56 Yield: 92.2%; oil; IR (ATR, cm⁻¹): 2818.4, 1734.5, 1501.4, 1450.3, 1240.1, 1028.6, 750.3; ¹H-NMR (200 MHz, CDCl₃) δ: 1.20 (t, 3H, J=7.4 Hz, CH₃), 1.28-1.34 (m, 4H, CH₂), 1.46-1.63 (m, 4H, CH₂), 2.21-2.35 (m, 4H, CH₂), 2.60 (s, 4H, piperazine), 3.06 (s, 4H, piperazine), 3.80 (s, 3H, OCH₃), 4.07 (q, 2H, J=7.2 Hz, J=7.4 Hz, COCH₂), 6.78-6.99 (m, 4H, ArH); ¹³C-NMR (50 MHz, CDCl₃) δ: 14.02, 24.65, 26.52, 27.03, 28.82, 34.03, 50.43, 53.29, 55.07, 58.53, 59.90, 110.90, 117.94, 120.75, 122.62, 141.19, 152.05, 173.55; MS: m/z [M+H]⁺calculated for C₂₀H₃₂N₂O₃ 349.24857, found 349.24825.

63

64 *Methyl 8-(4-(2-methoxyphenyl)piperazin-1-yl)octanoate (3g):*

65 Yield: 82.8 %; oil; IR (ATR, cm⁻¹): 2828.2, 1754.6, 1521.4, 1448.8, 1236.3, 1025.6, 755.4; ¹H-NMR (200 MHz, CDCl₃) δ: 1.26-1.32 (m, 6H, CH₂), 1.53-1.66 (m, 4H, CH₂), 2.27-2.43 (m, 4H, CH₂), 2.65-2.67 (m, 4H,piperazine), 3.11 (s, 4H, piperazine), 3.67 (s, OCH₃), 3.86 (s, 3H, OCH₃), 6.84-7.04 (m, 4H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ: 24.79, 26.74, 27.34, 29.09, 33.97, 50.56 , 51.33, 53.43, 55.25, 58.76, 111.06, 118.12, 120.91, 122.79, 141.33, 152.22, 174.24; MS: m/z [M+H]⁺ calculated for C₂₀H₃₂N₂O₃ 349.24857, found 349.24849.

71

72 *2-{{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}-1H-benzo[d]imidazole (5a):*

73 Yield: 16 %; oil; IR (ATR, cm⁻¹): 2817.2, 1502.0, 1455.7, 1240.3, 1026.5, 743.0; ¹H NMR (200 MHz, CDCl₃) δ: 2.75-2.80 (m, 4H, piperazine), 3.08-3.13 (m, 4H, piperazine), 3.84 (s, 3H, OCH₃), 3.91 (s, 2H, CH₂), 6.84-7.06 (m, 4H, ArH), 7.20-7.27 (m, 2H, ArH), 7.57-7.60 (m, 2H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ: 50.41 , 53.64, 55.31, 56.46, 111.23, 118.14, 120.93, 122.02, 122.40, 123.11, 140.90, 151.90, 152.23; MS: m/z [M+H]⁺ calculated for C₁₉H₂₂N₄O 323.18664, found 323.18515.

79

80 *2-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-1H-benzo[d]imidazole (5b):*

81 Yield: 36.5 %; oil; IR (ATR, cm⁻¹): 2818.4, 1500.6, 1456.7, 1240.0, 1026.3, 745.2; ¹H NMR
82 (200 MHz, CDCl₃) δ: 2.77-2.92 (m, 6H, 4H piperazine and CH₂), 3.11-3.18 (m, 6H, 4H piperazine
83 and CH₂) 3.87 (s, 3H, OCH₃), 6.87-7.04 (m, 4H, ArH), 7.17-7.25 (m, 2H, ArH), 7.52-7.57 (m,
84 2H,ArH); ¹³C NMR (50 MHz, CDCl₃) δ: 25.03, 50.76, 52.94, 55.33, 58.06, 111.23, 114.67,
85 118.13, 120.95, 122.02, 123.24, 140.78, 152.21, 154.52; MS: m/z [M+H]⁺ calculated for
86 C₂₀H₂₄N₄O 337.20229, found 337.20205.

87

88 *2-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}-1H-benzo[d]imidazole (5c):*

89 Yield: 55.7 %; oil; IR (ATR, cm⁻¹): 2825.5, 1500.7, 1452.9, 1241.4, 1026.5, 746.5; ¹H NMR
90 (200, MHz, CDCl₃) δ: 1.96-2.08 (m, 2H, CH₂), 2.64 (t, 2H, J=5.6 Hz, CH₂), 2.72 (s, 4H,
91 piperazine), 3.06-3.16 (m, 6H, 4H piperazine and CH₂), 3.85 (s, 3H, OCH₃), 6.86-7.05 (m, 4H,
92 ArH), 7.16-7.18 (m, 2H, ArH), 7.52-7.57 (m, 2H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ: 23.61,
93 28.90, 50.49, 53.25, 55.24, 58.72, 111.18, 114.46, 118.03, 120.98, 121.66, 123.18, 140.77, 152.18,
94 155.58; MS: m/z [M+H]⁺ calculated for C₂₁H₂₆N₄O 351.21794, found 351.21682.

95

96 *2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1H-benzo[d]imidazole (5d):*

97 Yield: 90.6 %; oil; IR (ATR, cm⁻¹): 2818.3, 1499.7, 1456.0, 1244.1, 1028.9, 793.3; ¹H NMR
98 (200 MHz, CDCl₃) δ: 1.55-1.70 (m, 2H,CH₂), 1.83-1.94 (m, 2H,CH₂), 2.43 (t, 2H, J=6.8 Hz, CH₂),
99 2.64 (s, 4H, piperazine), 2.98 (t, 2H, J=6.8 Hz, CH₂), 3.12(s, 4H,piperazine), 3.84 (s, 3H, OCH₃),
100 6.84-7.05 (m, 4H, ArH), 7.14-7.21 (m, 2H,ArH), 7.51-7.56 (m, 2H, ArH); ¹³C NMR (50 MHz,
101 CDCl₃) δ: 25.38, 25.81, 28.45, 50.34, 53.18, 55.24, 57.24, 111.19, 114.52, 118.16, 120.98, 121.88,
102 123.08, 138.57, 140.94, 152.19, 155.38; MS: m/z [M+H]⁺ calculated for C₂₂H₂₈N₄O 365.23359,
103 found 365.23263.

104

105 *2-{5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl}-1H-benzo[d]imidazole (5e):*

106 Yield: 43.0 %; brown crystals m.p. 63°C; IR (ATR, cm⁻¹): 2825.2, 1500.3, 1454.9, 1240.7,
107 1023.6, 752.8; ¹H NMR (200 MHz, CDCl₃) δ: 1.33-1.48 (m, 2H,CH₂), 1.60-1.75 (m, 2H, CH₂),
108 1.80-1.93 (m, 2H, CH₂), 2.54-2.62 (m, 2H, CH₂), 2.84-2.95 (m, 6H, CH₂ and 4H piperazine), 3.17-
109 3.19 (m, 4H, piperazine), 3.86 (s, 3H, OCH₃), 6.85-7.06 (m, 4H, ArH), 7.19-7.22 (m, 2H, ArH),

110 7.54-7.58 (m, 2H, ArH); ^{13}C NMR (50 MHz, CDCl_3) δ : 25.54, 26.62, 27.82, 28.84, 49.94, 53.00,
111 55.20, 57.97, 111.15, 114.50, 118.18, 120.95, 121.88, 123.10, 138.52, 140.78, 152.12, 155.31;
112 MS: m/z [M+H] $^+$ calculated for $\text{C}_{23}\text{H}_{30}\text{N}_4\text{O}$ 379.24924, found 379.24889.

113

114 2-{6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl}-1*H*-benzo[d]imidazole (**5f**):

115 Yield: 69.0 %; brown crystals m.p. 134 °C; IR (ATR, cm^{-1}): 2828.5, 1503.0; 1454.6, 1240.6,
116 1019.5, 750; ^1H NMR (200 MHz, CDCl_3) δ : 1.26-1.58 (m, 6H, CH_2), 1.76-1.92 (m, 2H, CH_2), 2.37
117 (t, 2H, $J=7.4$ Hz, CH_2), 2.61-2.65 (m, 4H, piperazine), 2.90 (t, 2H, $J=8$ Hz, CH_2), 3.11 (s, 4H,
118 piperazine), 3.85 (s, 3H, OCH_3), 6.84-7.04 (m, 4H, ArH), 7.18-7.27 (m, 2H, ArH), 7.51-7.58 (m,
119 2H, ArH); ^{13}C NMR (50 MHz, CDCl_3) δ : 26.12, 26.94, 28.00, 28.96, 29.13, 50.29, 53.20, 55.22,
120 58.37, 111.13, 114.54, 118.18, 121.97, 121.89, 123.02, 138.55, 141.01, 152.17, 155.38; MS: m/z
121 [M+H] $^+$ calculated for $\text{C}_{24}\text{H}_{32}\text{N}_4\text{O}$ 393.26489, found 393.26320.

122

123 2-{7-[4-(2-methoxyphenyl)piperazin-1-yl]heptyl}-1*H*-benzo[d]imidazole (**5g**):

124 Yield: 72.0 %; oil; IR (ATR, cm^{-1}): 2962.9, 1497.9, 1449.6, 1261.7, 1026.4, 744.5; ^1H NMR
125 (200 MHz, CDCl_3) δ : 1.26-1.49 (m, 8H, CH_2), 1.79-1.86 (m, 2H, CH_2), 2.38 (t, 2H, $J=7.4$ Hz,
126 CH_2), 2.68 (s, 4H, piperazine), 2.89 (t, 2H, $J=8$ Hz, CH_2), 3.13 (s, 4H, piperazine), 3.85 (s, 3H,
127 OCH_3), 6.84-6.94 (m, 4H, ArH), 7.19-7.24 (m, 2H, ArH), 7.52-7.56 (m, 2H, ArH); ^{13}C NMR (50
128 MHz, CDCl_3) δ : 26.45, 27.21, 28.11, 29.05, 29.29, 50.40, 53.35, 55.28, 58.65, 111.13, 114.64,
129 118.22, 120.98, 121.99, 123.01, 138.47, 141.11, 152.22, 155.26; MS: m/z [M+H] $^+$ calculated for
130 $\text{C}_{25}\text{H}_{34}\text{N}_4\text{O}$ 407.28054, found 407.28007.

131

132 5-methoxy-2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1*H*-benzo[d]imidazole (**5h**):

133 Yield: 88.0%; oil; IR (ATR, cm^{-1}): 2817.0, 1498.4, 1458.2, 1237.6, 1027, 751.2; ^1H NMR (200
134 MHz, CDCl_3) δ : 1.64-1.76 (m, 2H, CH_2), 1.84-1.98 (m, 2H, CH_2), 2.49 (t, 2H, $J=7.4$ Hz, CH_2),
135 2.70 (s, 4H, piperazine), 2.96 (t, 2H, $J=7.2$ Hz, CH_2), 3.16 (s, 4H, piperazine), 3.83 (s, 3H, OCH_3),
136 3.87 (s, 3H, OCH_3), 6.81-7.08 (m, 7H, ArH); ^{13}C NMR (50 MHz, CDCl_3) δ : 25.09, 25.87, 28.40,
137 50.54, 53.31, 55.33, 55.82, 57.09, 111.17, 118.18, 121.02, 123.17, 141.03, 152.26, 155.98; MS:
138 m/z [M+H] $^+$ calculated for $\text{C}_{23}\text{H}_{30}\text{N}_4\text{O}_2$ 395.24415, found 395.24331.

139

140 *5-methoxy-2-{5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl}-1H-benzo[d]imidazole (5i)*:

141 Yield: 73.0%; oil; IR (ATR, cm⁻¹): 2832.2, 1500.2, 1455.8, 1242.6, 1027.7, 752.9; ¹H NMR
142 (200 MHz, CDCl₃) δ: 1.38-1.45 (m, 2H, CH₂), 1.71-1.90 (m, 4H, CH₂), 2.77-2.94 (m, 4H, CH₂),
143 3.09 (s ,4H, piperazine), 3.28 (s, 4H,piperazine), 3.83 (s, 3H, OCH₃), 3.87 (s, 3H, OCH₃), 6.82-
144 6.92 (m, 4H, ArH), 7.02-7.08 (m, 2H, ArH), 7.46 (d, 2H, J=8Hz, ArH); ¹³C NMR (50 MHz, CDCl₃)
145 δ: 22.59, 22.97, 25.21, 27.00, 48.25, 52.18, 55.38, 55.80, 56.82, 97.42, 111.26, 111.63, 115.19,
146 118.51, 121.09, 123.92, 138.19, 139.72, 152.10, 154.72, 156.18; MS: m/z [M+H]⁺ calculated for
147 C₂₄H₃₂N₄O₂ 409.25980, found 409.26000.

148

149 *5-methoxy-2-{6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl}-1H-benzo[d]imidazole (5j)*:

150 Yield: 67.1%; oil; IR (ATR, cm⁻¹): 2856.0, 1501.3, 1457.2, 1247.5, 1026.2, 753.3; ¹H NMR
151 (200 MHz, CDCl₃) δ: 1.35-1.55 (m, 4H,CH₂), 1.63-1.88 (m, 2H,CH₂), 2.41 (t, 2H, J=8 Hz, CH₂),
152 2.67-2.72 (m ,4H, piperazine), 2.85 (t, 2H, J=7.4 Hz, CH₂), 3.10-3.15 (m, 4H, piperazine), 3.79 (s,
153 3H, OCH₃), 3.85 (s, 3H, OCH₃), 4.21-4.24 (m, 2H, CH₂), 6.81-7.03 (m, 4H, ArH), 7.38-7.43 (m,
154 1H, ArH), 7.50-7.55 (m, 1H, ArH), 7.67-7.74 (m, 1H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ: 22.85,
155 23.59, 25.83, 26.78, 27.82, 50.05, 53.11, 55.24, 55.71, 58.22, 97.59, 111.12, 115.16, 118.18,
156 120.95, 123.10, 130.85, 140.87, 152.14, 154.98, 155.91; MS: m/z [M+H]⁺ calculated for
157 C₂₅H₃₄N₄O₂ 423.27545, found 423.27570.

158

159 *5-methoxy-2-(7-(4-(2-methoxyphenyl)piperazin-1-yl)heptyl)-1H-benzo[d]imidazole (5k)*:

160 Yield: 62.3%; oil; IR (ATR, cm-1): 2927.7, 1501.3, 1499.0, 1453.5, 1240.3, 1026.6, 748.2; ¹H
161 NMR (200 MHz, CDCl₃) δ: 1.58 (s, 6H, CH₂), 2.16-2.23 (m, 2H, CH₂), 2.53 (s, 2H, CH₂), 2.85
162 (s, 6H, 4H piperazine and CH₂), 3.15 (s, 6H, 4H piperazine and CH₂), 3.81 (s, 3H, OCH₃), 3.85 (s,
163 3H, OCH₃), 6.84-7.01 (m 7H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ: 25.57, 27.13, 29.13, 49.53,
164 52.60, 55.31, 55.77, 57.9 , 97.67, 111.11, 118.29, 120.99, 123.20, 140.74, 152.14, 154.93, 155.96;
165 MS: m/z [M+H]⁺ calculated for C₂₆H₃₆N₄O₂ 437.29110, found 437.29115.

166

167 *5-chloro-2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1H-benzo[d]imidazole (5l):*
168 Yield: 88,4%; oil; IR (ATR, cm⁻¹): 2811.0, 1501.1, 1447.5, 1239.6, 1027.4, 751.2; ¹H NMR
169 (200 MHz, CDCl₃) δ: 1.59-1.69 (m, 2H, CH₂), 1.82-1.96 (m, 2H, CH₂), 2.39 (t, 2H, J=7.2 Hz, CH₂),
170 2.65 (s, 4H, piperazine), 2.96 (t, 2H, J=6.6 Hz, CH₂), 3.12 (s, 4H, piperazine), 3.84 (s, 3H, OCH₃),
171 6.84-7.02 (m, 4H, ArH), 7.12-7.17 (m, 1H, ArH), 7.39-7.50 (m, 2H, ArH); ¹³C-NMR (50 MHz,
172 CDCl₃) δ: 25.18, 25.83, 28.45, 50.38, 53.18, 55.24, 57.11, 111.12, 114.48, 115.19, 118.16, 120.97,
173 122.39, 123.17, 127.43, 140.79, 152.16, 156.67; MS: m/z [M+H]⁺ calculated for C₂₂H₂₇ClN₄O
174 399.19462, found 399.19367.
175
176 *5-chloro-2-{5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl}-1H-benzo[d]imidazole (5m):*
177 Yield: 65%; oil; IR (ATR, cm⁻¹): 2824.8, 1500.7, 1450.7, 1241.2, 1027.0, 749.9; ¹H NMR (200
178 MHz, CDCl₃) δ: 1.35-1.62 (m, 4H, CH₂), 1.77-1.91 (m, 2H, CH₂), 2.39 (t, 2H, J=8 Hz, CH₂), 2.64
179 (s, 4H, piperazine), 2.89 (t, 2H, J=8 Hz, CH₂), 3.11 (s, 4H, piperazine), 3.85 (s, 3H, OCH₃), 6.84-
180 7.06 (m, 4H, ArH), 7.13-7.18 (m, 1H, ArH), 7.40-7.50 (m, 2H, ArH); ¹³C NMR (50 MHz, CDCl₃)
181 δ: 25.96, 26.63, 27.67, 28.98, 50.38, 53.33, 55.27, 58.22, 111.15, 118.20, 121.00, 122.50, 123.13,
182 127.58, 140.96, 152.19, 156.32; MS: m/z [M+H]⁺ calculated for C₂₃H₂₉ClN₄O 413.21027, found
183 413.20891.
184
185 *5-chloro-2-{6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl}-1H-benzo[d]imidazole (5n):*
186 Yield: 74%; oil; IR (ATR, cm⁻¹): 2825.8, 1500.6, 1451.2, 1241.8, 1027.6, 750.4; ¹H NMR (200
187 MHz, CDCl₃) δ: 1.30-1.46 (m, 6H, CH₂), 1.72-1.83 (m, 2H, CH₂), 2.34 (t, 2H, J=8.6 Hz, CH₂),
188 2.63 (s, 4H, piperazine), 2.86 (t, 2H, J=7.4 Hz, CH₂), 3.09 (s, 4H, piperazine), 3.84 (s, 3H, OCH₃),
189 6.84-7.06 (m, 4H, ArH), 7.12-7.18 (m, 1H, ArH), 7.38-7.48 (m, 2H, ArH); ¹³C NMR (50 MHz,
190 CDCl₃) δ: 26.27, 26.96, 27.91, 28.89, 29.09, 50.45, 53.27, 55.22, 58.42, 111.10, 118.16, 120.97,
191 122.46, 123.08, 127.52, 140.98, 152.14, 156.51; MS: m/z [M+H]⁺ calculated for C₂₄H₃₁ClN₄O
192 427.22592, found 427.22408.
193
194

195
196
197
198

SUMMARY RESULTS OF MD SIMULATIONS

Table 1. D2DR-ligand key interactions observed in 100 ns MD simulations.

Residue	Leu 94	Trp 100	Asp 114	Cys 118	Ile 184	Phe 382	Trp 386	Phe 389	Phe 390	Tyr 408	Thr 412	Tyr 416
Ligand												
5e		54	81	68	27		76	65	42	65	37	
5f	21	31	79	36	40		82	74	20	33	42	
5h		67	81	58			84	85	24	36		
5i	50	89	80	75			96	84	42	22	30	
5j	36	94	82	73	24	32	98	53	31	25		
5l		22	82	64	26		95	75	34	37		
5m		75	84	69			78	50	49	63	40	
5n	32	42	80	32			82	68	35	28		32

199
200 D2DR-ligand interactions presented in more than 20% of MS simulation time are shown. Numbers provided in the
201 table refers to the percentage of the total simulation time one interaction observed to occur. Interacting residues in
202 OBS are shaded in grey colour; residues found in EBP are white.

203
204
205